Ulcerative Colitis
Below is a sample of existing clinical evidence:
“The use of MSCs can be evaluated as a new strategic direction for therapy UC. MSCs have powerful immunomodulatory effects, reduce the activity of autoimmune inflammation and stimulate the reparative process in the intestinal mucosa, thereby increasing the duration of remission, reduces risk of recurrence of disease, reduces the frequency of hospitalizations.”
– “Allogeneic mesenchymal stromal cells in patients with ulcerative colitis: two years of observation,” Lazebnik et al, Experimental & Clinical Gastroenterology, 2010